tiprankstipranks
Advertisement
Advertisement
Abeona Therapeutics Updates Investor Presentation Under Regulation FD
PremiumCompany AnnouncementsAbeona Therapeutics Updates Investor Presentation Under Regulation FD
2M ago
Abeona Advances ABO-701 T-Cell Therapy Toward IND
Premium
Company Announcements
Abeona Advances ABO-701 T-Cell Therapy Toward IND
2M ago
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
Premium
Company Announcements
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
2M ago
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
PremiumCompany AnnouncementsAbeona Therapeutics Tightens Shareholder Meeting and Governance Rules
4M ago
Early-Stage ZEVASKYN Momentum and Attractive Economics Underscore Abeona’s Undervalued Growth Potential and $20 Buy Rating
Premium
Ratings
Early-Stage ZEVASKYN Momentum and Attractive Economics Underscore Abeona’s Undervalued Growth Potential and $20 Buy Rating
5M ago
Abeona Therapeutics Balances Big Windfall With Slow Ramp
Premium
Company Announcements
Abeona Therapeutics Balances Big Windfall With Slow Ramp
5M ago
ABEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsABEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
Early ZEVASKYN Launch Traction and Robust Reimbursement Support Abeona Buy Rating and $20 Target
Premium
Ratings
Early ZEVASKYN Launch Traction and Robust Reimbursement Support Abeona Buy Rating and $20 Target
5M ago
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
Premium
Company Announcements
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100